REFERENCES
2. Barnes BM, Nelson L, Tighe A, et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med 2021;13:140.
3. Morden CR, Farrell AC, Sliwowski M, et al. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples. Gynecol Oncol 2021;161:769-78.
4. Reid BM, Permuth JB, Chen YA, et al. Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2019;28:1117-26.
5. Hu Z, Artibani M, Alsaadi A, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 2020;37:226-42.e7.
6. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284-96.
7. Lu M, Fan Z, Xu B, et al. Using machine learning to predict ovarian cancer. Int J Med Inform 2020;141:104195.
8. Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol 2021;137:108-21.
9. Yang J, Antin P, Berx G, et al. EMT International Association (TEMTIA). Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2020;21:341-52.
10. Rho SB, Byun HJ, Kim BR, Lee CH. Snail promotes cancer cell proliferation via its interaction with the BIRC3. Biomol Ther 2022;30:380-8.
11. Baulida J, García de Herreros A. Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy. Biochim Biophys Acta 2015;1856:55-61.
12. Wang H, Chirshev E, Hojo N, et al. The epithelial-mesenchymal transcription factor SNAI1 represses transcription of the tumor suppressor miRNA let-7 in cancer. Cancers 2021;13:1469.
13. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009;27:2059-68.
15. Rowe RG, Li XY, Hu Y, et al. Mesenchymal cells reactivate snail1 expression to drive three-dimensional invasion programs. J Cell Biol 2009;184:399-408.
16. Galindo-Pumariño C, Collado M, Castillo ME, et al. SNAI1-expressing fibroblasts and derived-extracellular matrix as mediators of drug resistance in colorectal cancer patients. Toxicol Appl Pharmacol 2022;450:116171.
17. Sala L, Franco-Valls H, Stanisavljevic J, et al. Abrogation of myofibroblast activities in metastasis and fibrosis by methyltransferase inhibition. Int J Cancer 2019;145:3064-77.
18. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-37.
19. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
20. Sharma A, Blériot C, Currenti J, Ginhoux F. Oncofetal reprogramming in tumour development and progression. Nat Rev Cancer 2022;22:593-602.
21. Grau Y, Carteret C, Simpson P. Mutations and chromosomal rearrangements affecting the expression of snail, a gene involved in embryonic patterning in DROSOPHILA MELANOGASTER. Genetics 1984;108:347-60.
22. Ciruna B, Rossant J. FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. Dev Cell 2001;1:37-49.
23. Dale JK, Malapert P, Chal J, et al. Oscillations of the snail genes in the presomitic mesoderm coordinate segmental patterning and morphogenesis in vertebrate somitogenesis. Dev Cell 2006;10:355-66.
24. Tyser RCV, Mahammadov E, Nakanoh S, Vallier L, Scialdone A, Srinivas S. Single-cell transcriptomic characterization of a gastrulating human embryo. Nature 2021;600:285-9.
25. Dubrulle J, McGrew MJ, Pourquié O. FGF signaling controls somite boundary position and regulates segmentation clock control of spatiotemporal Hox gene activation. Cell 2001;106:219-32.
26. Aulehla A, Wehrle C, Brand-Saberi B, et al. Wnt3a plays a major role in the segmentation clock controlling somitogenesis. Dev Cell 2003;4:395-406.
27. Chu LF, Mamott D, Ni Z, et al. An in vitro human segmentation clock model derived from embryonic stem cells. Cell Rep 2019;28:2247-55.e5.
28. Dias A, Lozovska A, Wymeersch FJ, et al. A Tgfbr1/Snai1-dependent developmental module at the core of vertebrate axial elongation. Elife 2020;9:e56615.
29. Nicholson HA, Sawers L, Clarke RG, Hiom KJ, Ferguson MJ, Smith G. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer. Br J Cancer 2022;127:1340-51.
30. Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumour Biol 2017;39:1010428317712592.
31. Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
32. Batlle E, Sancho E, Francí C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
33. Stemmler MP, Eccles RL, Brabletz S, Brabletz T. Non-redundant functions of EMT transcription factors. Nat Cell Biol 2019;21:102-12.
34. Stone RC, Pastar I, Ojeh N, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res 2016;365:495-506.
35. Gharbia FZ, Abouhashem AS, Moqidem YA, et al. Adult skin fibroblast state change in murine wound healing. Sci Rep 2023;13:886.
36. Yan C, Grimm WA, Garner WL, et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am J Pathol 2010;176:2247-58.
37. Qi R, Wang J, Jiang Y, et al. Snai1-induced partial epithelial-mesenchymal transition orchestrates p53-p21-mediated G2/M arrest in the progression of renal fibrosis via NF-κB-mediated inflammation. Cell Death Dis 2021;12:44.
38. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019;20:69-84.
39. Miyoshi A, Kitajima Y, Kido S, et al. Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer 2005;92:252-8.
40. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
41. Jolly MK, Murphy RJ, Bhatia S, et al. Measuring and modelling the epithelial- mesenchymal hybrid state in cancer: clinical implications. Cells Tissues Organs 2022;211:110-33.
43. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol 2019;29:212-26.
44. Tan TZ, Miow QH, Huang RY, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 2013;5:1051-66.
45. Pang QY, Tan TZ, Sundararajan V, et al. 3D genome organization in the epithelial-mesenchymal transition spectrum. Genome Biol 2022;23:121.
46. Strauss R, Li ZY, Liu Y, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011;6:e16186.
47. Huang RY, Wong MK, Tan TZ, et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 2013;4:e915.
48. Klymenko Y, Kim O, Stack MS. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers 2017;9:104.
49. Gonzalez VD, Samusik N, Chen TJ, et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep 2018;22:1875-88.
50. Takano S, Reichert M, Bakir B, et al. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev 2016;30:233-47.
51. Watanabe K, Villarreal-Ponce A, Sun P, et al. Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev Cell 2014;29:59-74.
52. Hong T, Watanabe K, Ta CH, Villarreal-Ponce A, Nie Q, Dai X. An Ovol2-Zeb1 mutual inhibitory circuit governs bidirectional and multi-step transition between epithelial and mesenchymal states. PLoS Comput Biol 2015;11:e1004569.
53. Jolly MK, Tripathi SC, Jia D, et al. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 2016;7:27067-84.
54. Bocci F, Jolly MK, Tripathi SC, et al. Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling. J R Soc Interface 2017;14:20170512.
55. Varankar SS, More M, Abraham A, et al. Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines. Carcinogenesis 2020;41:515-26.
56. Ocaña OH, Córcoles R, Fabra A, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012;22:709-24.
57. Strauss R, Sova P, Liu Y, et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res 2009;69:5115-25.
58. Muñoz-Galván S, Carnero A. Leveraging genomics, transcriptomics, and epigenomics to understand the biology and chemoresistance of ovarian cancer. Cancers 2021;13:4029.
59. Yu KH, Hu V, Wang F, et al. Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. BMC Med 2020;18:236.
60. Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z. RNA sequencing (RNA-Seq) and its application in ovarian cancer. Gynecol Oncol 2019;152:194-201.
61. Tothill RW, Tinker AV, George J, et al. Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
62. Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
63. Hollis RL, Meynert AM, Michie CO, et al. Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification. Clin Cancer Res 2022;28:3546-56.
64. Cook DP, Vanderhyden BC. Context specificity of the EMT transcriptional response. Nat Commun 2020;11:2142.
65. Kan T, Wang W, Ip PP, et al. Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene 2020;39:4227-40.
66. Xu J, Fang Y, Chen K, et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin Cancer Res 2022;28:3590-602.
67. McCorry AM, Loughrey MB, Longley DB, Lawler M, Dunne PD. Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. J Pathol 2018;246:422-6.
68. Stanisavljevic J, Loubat-Casanovas J, Herrera M, et al. Snail1-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis. Cancer Res 2015;75:284-95.
69. Stur E, Corvigno S, Xu M, et al. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience 2022;25:103923.
70. Zhu Y, Ferri-Borgogno S, Sheng J, et al. SIO: a spatioimageomics pipeline to identify prognostic biomarkers associated with the ovarian tumor microenvironment. Cancers 2021;13:1777.
71. Imai T, Horiuchi A, Wang C, et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of snail in ovarian carcinoma cells. Am J Pathol 2003;163:1437-47.
72. Craene B, van Roy F, Berx G. Unraveling signalling cascades for the snail family of transcription factors. Cell Signal 2005;17:535-47.
73. Ichikawa MK, Endo K, Itoh Y, et al. Ets family proteins regulate the EMT transcription factors snail and ZEB in cancer cells. FEBS Open Bio 2022;12:1353-64.
74. Hapke RY, Haake SM. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett 2020;487:10-20.
75. Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev 2014;33:17-39.
76. Mogi K, Yoshihara M, Iyoshi S, et al. Ovarian cancer-associated mesothelial cells: transdifferentiation to minions of cancer and orchestrate developing peritoneal dissemination. Cancers 2021;13:1352.
77. Worzfeld T, Pogge von Strandmann E, Huber M, et al. The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol 2017;7:24.
78. Cho A, Howell VM, Colvin EK. The extracellular matrix in epithelial ovarian cancer - a piece of a puzzle. Front Oncol 2015;5:245.
79. Gao Q, Yang Z, Xu S, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med 2019;216:688-703.
80. Madden EC, Gorman AM, Logue SE, Samali A. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer 2020;6:489-505.
81. Wang S, Jia J, Liu D, et al. Matrix metalloproteinase expressions play important role in prediction of ovarian cancer outcome. Sci Rep 2019;9:11677.
82. Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol 2015;44-6:200-6.
83. Pang L, Li Q, Li S, et al. Membrane type 1-matrix metalloproteinase induces epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: Observations from clinical and in vitro analyses. Sci Rep 2016;6:22179.
84. Li Y, He J, Wang F, et al. Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer. World J Surg Oncol 2020;18:181.
85. Liu Y, Sun X, Feng J, et al. MT2-MMP induces proteolysis and leads to EMT in carcinomas. Oncotarget 2016;7:48193-205.
86. Kurrey NK, K A, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005;97:155-65.
87. Jin H, Yu Y, Zhang T, et al. Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer 2010;126:2102-11.
88. Ohkubo T, Ozawa M. The transcription factor snail downregulates the tight junction components independently of E-cadherin downregulation. J Cell Sci 2004;117:1675-85.
89. Whiteman EL, Liu CJ, Fearon ER, Margolis B. The transcription factor snail represses Crumbs3 expression and disrupts apico-basal polarity complexes. Oncogene 2008;27:3875-9.
90. Massoumi R, Kuphal S, Hellerbrand C, et al. Down-regulation of CYLD expression by snail promotes tumor progression in malignant melanoma. J Exp Med 2009;206:221-32.
91. Kashyap A, Zimmerman T, Ergül N, et al. The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis. Oncogene 2013;32:1396-407.
92. Unternaehrer JJ, Zhao R, Kim K, et al. The epithelial-mesenchymal transition factor snail paradoxically enhances reprogramming. Stem Cell Reports 2014;3:691-8.
93. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2004;2:4.
94. Guaita S, Puig I, Franci C, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 2002;277:39209-16.
95. Siemens H, Jackstadt R, Hünten S, et al. MiR-34 and snail form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011;10:4256-71.
96. Díaz-López A, Díaz-Martín J, Moreno-Bueno G, et al. Zeb1 and snail1 engage miR-200f transcriptional and epigenetic regulation during EMT. Int J Cancer 2015;136:E62-73.
97. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907.
98. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.
99. Beach S, Tang H, Park S, et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008;27:2243-8.
100. Kim NH, Cha YH, Lee J, et al. Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress. Nat Commun 2017;8:14374.
101. Ganesan R, Mallets E, Gomez-Cambronero J. The transcription factors Slug (SNAI2) and snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion. Mol Oncol 2016;10:663-76.
102. Escriva M, Peiró S, Herranz N, et al. Repression of PTEN phosphatase by snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 2008;28:1528-40.
103. Sundararajan V, Tan M, Tan TZ, Ye J, Thiery JP, Huang RY. SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition. Sci Rep 2019;9:8295.
104. Pálmer HG, Larriba MJ, García JM, et al. The transcription factor Snail represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 2004;10:917-9.
105. Ly TM, Chen YC, Lee MC, et al. Snail upregulates transcription of FN, LEF, COX2, and COL1A1 in hepatocellular carcinoma: a general model established for snail to transactivate mesenchymal genes. Cells 2021;10:2202.
106. Taki M, Abiko K, Baba T, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun 2018;9:1685.
107. Jordà M, Olmeda D, Vinyals A, et al. Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci 2005;118:3371-85.
108. Baulida J, Díaz VM, Herreros AG. Snail1: a transcriptional factor controlled at multiple levels. J Clin Med 2019;8:757.
109. Chen L, Yao Y, Sun L, et al. Snail driving alternative splicing of CD44 by ESRP1 enhances invasion and migration in epithelial ovarian cancer. Cell Physiol Biochem 2017;43:2489-504.
110. Cui H, Hu Y, Guo D, et al. DNA methyltransferase 3A isoform b contributes to repressing E-cadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer. Oncogene 2018;37:4358-71.
111. Dong P, Xiong Y, Watari H, et al. MiR-137 and miR-34a directly target snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res 2016;35:132.
112. Pearson GW. Control of invasion by epithelial-to-mesenchymal transition programs during metastasis. J Clin Med 2019;8:646.
113. Aiello NM, Maddipati R, Norgard RJ, et al. EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell 2018;45:681-95.e4.
114. Loret N, Denys H, Tummers P, Berx G. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers 2019;11:838.
115. Jolly MK, Somarelli JA, Sheth M, et al. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther 2019;194:161-84.
116. Pal A, Barrett TF, Paolini R, Parikh A, Puram SV. Partial EMT in head and neck cancer biology: a spectrum instead of a switch. Oncogene 2021;40:5049-65.
117. Liao TT, Yang MH. Hybrid epithelial/mesenchymal state in cancer metastasis: clinical significance and regulatory mechanisms. Cells 2020;9:623.
118. George JT, Jolly MK, Xu S, Somarelli JA, Levine H. Survival outcomes in cancer patients predicted by a partial EMT gene expression scoring metric. Cancer Res 2017;77:6415-28.
119. Li CF, Chen JY, Ho YH, et al. Snail-induced claudin-11 prompts collective migration for tumour progression. Nat Cell Biol 2019;21:251-62.
120. Pradeep S, Kim SW, Wu SY, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014;26:77-91.
121. Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol Oncol 2017;145:361-5.
122. Aponte PM, Caicedo A. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cells Int 2017;2017:5619472.
123. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
124. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005;65:3025-9.
125. Suster N, Virant-Klun I. Presence and role of stem cells in ovarian cancer. World J Stem Cells 2019;11:383-97.
126. Hahn S, Jackstadt R, Siemens H, Hünten S, Hermeking H. Snail and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J 2013;32:3079-95.
127. Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846-54.
128. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487-95.
129. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep 2010;11:670-7.
130. Li Q, Liu W, Chiu PCN, Yeung WSB. Mir-let-7a/g enhances uterine receptivity via suppressing Wnt/β-Catenin under the modulation of ovarian hormones. Reprod Sci 2020;27:1164-74.
131. Yang WH, Lan HY, Huang CH, et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol 2012;14:366-74.
132. Worringer KA, Rand TA, Hayashi Y, et al. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell 2014;14:40-52.
133. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888.
134. Chiou SH, Wang ML, Chou YT, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010;70:10433-44.
135. Yin X, Zhang BH, Zheng SS, et al. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/snail signaling. J Hematol Oncol 2015;8:23.
136. Jolly MK, Jia D, Boareto M, et al. Coupling the modules of EMT and stemness: a tunable ‘stemness window’ model. Oncotarget 2015;6:25161-74.
137. Jolly MK, Huang B, Lu M, Mani SA, Levine H, Ben-Jacob E. Towards elucidating the connection between epithelial-mesenchymal transitions and stemness. J R Soc Interface 2014;11:20140962.
138. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets 2013;13:963-72.
139. Saxena K, Jolly MK, Balamurugan K. Hypoxia, partial EMT and collective migration: emerging culprits in metastasis. Transl Oncol 2020;13:100845.
140. Kröger C, Afeyan A, Mraz J, et al. Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proc Natl Acad Sci USA 2019;116:7353-62.
141. Hojo N, Huisken AL, Wang H, et al. Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer. Sci Rep 2018;8:8704.
142. Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol 2018;53:265-81.
143. Dong C, Yuan T, Wu Y, et al. Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013;23:316-31.
144. Grassi ML, Palma CS, Thomé CH, Lanfredi GP, Poersch A, Faça VM. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. J Proteomics 2017;151:2-11.
145. Leung D, Price ZK, Lokman NA, et al. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism. J Transl Med 2022;20:556.
146. Kobayashi H. Recent advances in understanding the metabolic plasticity of ovarian cancer: a systematic review. Heliyon 2022;8:e11487.
147. Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:77-102.
148. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:191-226.
149. Kim H, Xu H, George E, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun 2020;11:3726.
150. Wang H, Li JM, Wei W, et al. Regulation of ATP-binding cassette subfamily B member 1 by snail contributes to chemoresistance in colorectal cancer. Cancer Sci 2020;111:84-97.
151. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011;2:e179.
152. Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012;12:91.
153. Seo J, Ha J, Kang E, Cho S. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance. Arch Pharm Res 2021;44:281-92.
154. Sundararajan V, Tan M, Zea Tan T, et al. SNAI1-driven sequential EMT changes attributed by selective chromatin enrichment of RAD21 and GRHL2. Cancers 2020;12:1140.
155. Harney AS, Meade TJ, LaBonne C. Targeted inactivation of snail family EMT regulatory factors by a Co(III)-Ebox conjugate. PLoS One 2012;7:e32318.
156. Lee SH, Shen GN, Jung YS, et al. Antitumor effect of novel small chemical inhibitors of snail-p53 binding in K-Ras-mutated cancer cells. Oncogene 2010;29:4576-87.
157. Ferrari-Amorotti G, Fragliasso V, Esteki R, et al. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res 2013;73:235-45.
158. Ferrari-Amorotti G, Chiodoni C, Shen F, et al. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. Neoplasia 2014;16:1047-58.
159. Li HM, Bi YR, Li Y, et al. A potent CBP/p300-snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer. Sci Adv 2020;6:eaaw8500.
160. Ren BX, Li Y, Li HM, Lu T, Wu ZQ, Fu R. The antibiotic drug trimethoprim suppresses tumour growth and metastasis via targeting snail. Br J Pharmacol 2022;179:2659-77.
